Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Aug 14;16(1):170.
doi: 10.1186/s12957-018-1465-8.

Prognostic and clinicopathological value of Beclin-1 expression in hepatocellular carcinoma: a meta-analysis

Zhiqiang Qin  1 , Xinjuan Yu  2 , Mei Lin  3 , Jinkun Wu  1 , Shupei Ma  4 , Ning Wang  1
Affiliations
Meta-Analysis

Prognostic and clinicopathological value of Beclin-1 expression in hepatocellular carcinoma: a meta-analysis

Zhiqiang Qin et al. World J Surg Oncol. .

Abstract

Background: The abnormal expression of Beclin-1 has recently been investigated in a variety of tumors. However, previous studies have obtained contradicting results regarding the clinical and prognostic value of Beclin-1 in hepatocellular carcinoma (HCC). We performed a meta-analysis to clarify the prognostic value of Beclin-1 and its correlations with clinical pathological parameters in HCC.

Methods: Relevant studies were systematically retrieved from PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Wan Fang and Chinese VIP databases. We used the Newcastle-Ottawa scale (NOS) to estimate the quality of the involved studies.

Results: Ten eligible studies with 1086 HCC patients were included in this study. Our results showed that decreased Beclin-1 expression in HCC related to histological grade [poor-undifferentiated vs. well-moderate: odds ratio (OR) = 2.34, 95% confidence interval (CI) = 1.65-3.32, P < 0.00001]. The pooled hazard ratio (HR) (HR = 1.43, 95% CI = 1.17-1.75, P = 0.0004) indicated that decreased Beclin-1 expression correlated with poor overall survival (OS).

Conclusions: This meta-analysis indicated that decreased Beclin-1 expression might relate to poor differentiation and unfavorable outcome in HCC.

Keywords: Beclin-1; Clinicopathological factors; Hepatocellular carcinoma (HCC); Meta-analysis; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow chart of study selection
Fig. 2
Fig. 2
Forest plot of studies assessing the relationship between Beclin-1 expression and a age and b gender
Fig. 3
Fig. 3
Forest plot of studies assessing the relationship between Beclin-1 expression and a liver cirrhosis and b HBsAg
Fig. 4
Fig. 4
Forest plot of studies assessing the relationship between Beclin-1 expression and a tumor size and b tumor number
Fig. 5
Fig. 5
Forest plot of studies assessing the relationship between Beclin-1 expression and a histological grade and b TNM stage
Fig. 6
Fig. 6
Forest plot of studies assessing the relationship between Beclin-1 expression and OS in HCC patients
Fig. 7
Fig. 7
Funnel plot for assessing publication bias of the relationship between Beclin-1 expression and a age, b gender, c liver cirrhosis, and d HBsAg
Fig. 8
Fig. 8
Funnel plot for assessing publication bias of the relationship between Beclin-1 expression. a Tumor size. b Tumor number. c Histological grade. d TNM stage. e OS
See this image and copyright information in PMC

References

    1. Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis. Int J Oncol. 2013;42:1133–1138. doi: 10.3892/ijo.2013.1829. - DOI - PMC - PubMed
    1. Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguri M, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381–388. doi: 10.1016/S1072-7515(00)00700-6. - DOI - PubMed
    1. Schlachterman A, Craft WW, Jr, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21:8478–8491. doi: 10.3748/wjg.v21.i28.8478. - DOI - PMC - PubMed
    1. Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23–43. doi: 10.1016/j.cld.2014.09.002. - DOI - PubMed
    1. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717–1721. doi: 10.1126/science.290.5497.1717. - DOI - PMC - PubMed

Publication types